

Bhutan Support for Inactivated Polio Vaccine (IPV)

This Decision Letter sets out the Programme Terms of a Programme.

1. Country: Bhutan			
2. Grant number(s): 1518-BTN-25d-X /15-BTN-08h-Y/ 18-BTN-25f-X			
3. Date of Decision Letter: 9 April 2018 (This Decision Letter replaces the previous Decision Letter dated 14 December 2017)			
4. Date of the Partnership Framework Agreement: 16 May 2014			
5. Programme title: NVS, IPV routine / fractional IPV Catch-up through Routine Immunisation			
6. Vaccine type: Inactivated Polio Vaccine (IPV)			
7. Requested product presentation and formulation of vaccine¹: Inactivated Polio Vaccine, 1 dose(s) per vial, LIQUID / Fractional use of Inactivated Polio Vaccine, 1 dose(s) per vial, LIQUID			
8. Programme duration²: 2015 - 2018			
9. Indicative Programme Budget: (subject to the terms of the Partnership Framework Agreement) <i>Please note that endorsed or approved amounts for 2019 will be communicated in due course, taking into account updated information on country requirements and following Gavi's review and approval processes.</i>			
	2015-2017	2018	Total ³
Routine Programme (US\$) IPV	63,886 ⁴	41,000	104,886
Catch-up vaccination (US\$) fIPV		15,500	15,500
Total Budget (US\$)	63,886	56,500	120,386
10. Vaccine introduction grant / Product switch grant: A VIG of US\$100,000 was disbursed on 29 August 2014.			
11. Indicative Annual Amounts: (subject to the terms of the Partnership Framework Agreement) ⁵			
Number of vaccines to be purchased with Gavi funds	2015-2017	2018	

¹ Please refer to section 18 for additional information on IPV presentation.

² This is the entire duration of the Programme.

³ This is the total amount endorsed by Gavi for 2015 to 2018.

⁴ This is the consolidated amount for all previous years. Annual amounts prior to 2017 include the costs of injection safety devices. Annual amounts for 2017 onwards include only vaccine costs and freight.

⁵ This is the amount that Gavi has approved.

IPV Routine Programme (doses)		14,000						
IPV Routine Programme (US\$)	63,886	41,000						
Catch-up vaccination, fractional use of IPV (doses)		5,300						
Catch-up vaccination (US\$)		15,500						
12. Procurement agency: UNICEF								
13. Self-procurement: Not applicable								
14. Co-financing obligations: Not applicable Gavi's usual co-financing requirements do not apply to IPV. However, Bhutan is encouraged to contribute to vaccine and/or supply costs for IPV.								
15. Operational support for catch-up campaigns: Not applicable								
16. Additional reporting requirements:								
<table border="1"> <thead> <tr> <th>Reports and other information</th> <th>Due dates</th> </tr> </thead> <tbody> <tr> <td>To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.</td> <td>15 May 2018</td> </tr> <tr> <td>In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.</td> <td>To be agreed with Secretariat</td> </tr> </tbody> </table>			Reports and other information	Due dates	To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2018	In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat
Reports and other information	Due dates							
To prepare for the annual procurement of vaccines, Country shall submit the following information in May each year: number of children to be vaccinated, vaccine stock levels including buffer stock, wastage rates, any proposed changes in presentation or minimum co-financing levels and vaccines received.	15 May 2018							
In accordance with applicable Gavi processes, Country shall report on programmatic and financial performance.	To be agreed with Secretariat							
17. Financial clarifications: Not applicable								
18. Other conditions:								
<p>Due to unprecedented demand for IPV and the challenges to scale up production capacities, the global IPV supply remains constrained and is unlikely to meet all country requirements in the short term. As a consequence, the actual presentation and number of doses shipped may differ from those specified in this Decision Letter. In order to mitigate these circumstances, you are strongly encouraged to optimally manage available supply and follow recommendations and guidelines from WHO and UNICEF to reduce vaccine wastage.</p>								

Signed by,
On behalf of Gavi



Hind Khatib-Othman
Managing Director, Country Programmes
9 April 2018